Sample size computations for PK/PD population models

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 32, Issue 5-6, 2005, Pages 685-701

  Kang, Dongwoo ^a   Schwartz, Janice B ^b   Verotta, Davide ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Jewish Home ^*  (United States)

Author keywords

PK PD models; Sample size; Simulation methods

Indexed keywords

ARTICLE; CHI SQUARE DISTRIBUTION; MATHEMATICAL COMPUTING; METHODOLOGY; MONTE CARLO METHOD; POPULATION MODEL; POPULATION RESEARCH; PRIORITY JOURNAL; SAMPLE SIZE; STATISTICAL ANALYSIS; STEADY STATE;

ALGORITHMS; CLINICAL TRIALS; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HUMANS; LINEAR MODELS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PHARMACOKINETICS; PHARMACOLOGY; SAMPLE SIZE;

EID: 28844482941     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-005-0078-3     Document Type: Article

References (27)

1. D.A. Bloch 1986 Sample size requirements and the cost of a randomized clinical trial with repeated measurements Stat. Med. 5 663 667
2. E.F. Vonesh M.A. Schork 1986 Sample sizes in the multivariate analysis of repeated measurements Biometrics 42 601 610
3. J. Rochon 1998 Application of GEE procedures for sample size calculations in repeated measures experiments Stat. Med. 17 1643 1658
4. S. Akselrod S. Eliash O. Oz S. Cohen 1988 Hemodynamic regulation in SHR: investigation by spectral analysis Am. J. Physiol. 253 H176 183
5. K.-J. Lui 1991 Sample sizes for repeated measurements in dichotomous data Stat. Med. 10 463 472
6. K.-J. Lui W.G. Cumberland 1992 Sample size requirement for repeated measurements in continuous data Stat. Med. 11 633 641
7. K.-J. Lui 1997 Sample size determination for repeated measurements in bioequivalence test J. Pharmacokinetic Biop. 25 507 513
8. S.-C. Chow H. Wang 2001 On sample size calculation in bioequivalence trials J. Pharmacokinetic Biop. 28 155 169
9. D. Dey P. Muller D. Sinha 1998 in Practical Nonparametric and Semiparametric Bayesian Statistics Springer New York
10. D. Kang J.B. Schwartz D.A Verotta 2004 Sample size computation method for nonlinear mixed effects models with applications to pharmacokinetics models Stat. Med. 23 2551 2566
11. M. Davidian D.M. Giltinan 1995 Nonlinear Models for Repeated Measurment Data Chapman and Hall New York, New York
12. A. Wald 1943 Tests of statistical hypotheses concerning several parameters when the number of observations is large T. Am. Math. Soc. 54 426 482
13. L. Aarons S. Vozeh M. Wenk P. Weiss F. Follath 1989 Population pharmacokinetics of tobramycin Brit. J. Clin. Pharmaco. 28 305 314
14. D.R. Abernethy J.B. Schwartz E.L. Todd R. Luchi E. Snow 1986 Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients: altered electrocardiographics and hypotensive responses Ann. Int. Med. 105 329 336
15. Numerical Recipes. Cambridge University Press. http://www.nr.com/
16. A. J. Boeckmann, S. L. Beal, and L. B. Sheiner. NONMEM V Users Guides, (1998)
17. C. Cobelli A. Lepschy G.R. Jacur 1979 Identifiability of Compartmental systems and related structural properties Math. Biosci. 44 1 18
18. G. Segre 1968 Kinetics of interaction between drugs and biological systems Il Farmaco 23 907 918
19. D. Verotta 1996 Concepts, properties, and applications of linear systems to describe the distribution, indentify input, and control endogenous substances and drugs in biological systems Criti. Rev. Bioeng. 24 73 139
20. N.L. Dayneka V. Garg W.J. Jusko 1993 Comparison of four basic models of indirect pharmacodynamic responses J. Pharmacokinet. Biop. 21 457 478
21. D. Kang 2003 Population analyses of sustained-release verapamil in patients: Effects of sex, race, and smoking Clini. Pharmacol. Ther. 73 31 40
22. J.J. Jacquez P. Greif 1985 Numerical parameter identifiability and estimability: integrating identifiability, estimability, and optimal sampling design Math. Biosci. 77 201 227
23. E. Walter L. Pronzato 1987 Optimal experiment design for nonlinear models subject to large prior uncertainties Am. J. Physiol. 253 R530 R534 (Regulatory Integrative Comp Physiol 22)
24. M. Tod M. Mentre F. Merle Y. Mallet 1998 A Robust optimal design for the estimation of hyperparameters in population pharmacokinetics 26 689 716
25. E.M. Landaw 1985 in Variability in Drug Therapy: Description, estimation, and control Raven Press New York 187 200
26. S. Retout F. Mentre 2003 Optimization of Individual and Population Designs using Splus J. Pharmacokinet Phar. 30 417 443
27. U. Wahlby M.R. Bouw E.N. Jonsson M.O. Karlsson 2002 Assessment of type I error rates for the statistical sub-model in NONMEM J. Pharmacokinet Phar. 29 251 269